Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Future of Momelotinib in Myelofibrosis Uncertain After Phase III Update

November 18th 2016

Outcomes were mixed for momelotinib in topline results from 2 phase III myelofibrosis trials announced by Gilead Sciences, the company developing the investigational JAK1/2 inhibitor.

Expert Highlights Advances in Myeloproliferative Neoplasms

November 1st 2016

Both myelofibrosis and polycythemia vera are myeloproliferative neoplasms with very specific characteristics and treatment strategies.

Dr. Mesa on NCCN Guidelines for MPNs

October 26th 2016

Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN guidelines for treatment of patients with myeloproliferative neoplasms (MPNs).

Dr. Ruben Mesa on Impact of New NCCN Guidelines for MPN

October 8th 2016

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the significance of the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).

Mesa Maps Out Present and Future of Myelofibrosis Care

October 1st 2016

Ruben Mesa, MD, discussed the latest NCCN treatment guidelines for myelofibrosis and emerging treatments in the field.

Dr. Ruben Mesa on New NCCN Guidelines for MPNs

October 1st 2016

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN). Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).

Unmet Needs in Polycythemia Vera

September 29th 2016

Role of Ruxolitinib in Polycythemia Vera

September 29th 2016

Looking Beyond Hematocrit Control in Polycythemia Vera

September 29th 2016

Polycythemia Vera: Considerations in Hematocrit Control

September 29th 2016

Patient Selection for Treatment of Polycythemia Vera

September 29th 2016

Assessing Risk in Polycythemia Vera

September 29th 2016

Understanding Polycythemia Vera

September 29th 2016

Unmet Needs in Myelofibrosis

September 29th 2016

Therapeutic Response with JAK Inhibition in Myelofibrosis

September 29th 2016

Cytopenia-Related Considerations in Myelofibrosis

September 29th 2016

Optimal Timing of JAK Inhibition in Myelofibrosis

September 29th 2016

Role for JAK Inhibition in Myelofibrosis

September 29th 2016

Myelofibrosis: Considerations for Transplant or Surgery

September 29th 2016

When to Initiate Therapy in Myelofibrosis

September 29th 2016